Uncategorized Archives - Page 48 of 145

ThursdayJul 28, 2022 10:30 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Cleared for Historic Study, Begins Enrolling Participants

Company receives FDA “may proceed” letter and investigational new drug (“IND”) application clearance Enrollment for Phase 1/2a trial has already started Upcoming trial is first time a psilocybin analog will be evaluated for MDD treatment Studies show psychedelic-based treatments may have potential to revolutionize mental healthcare, but few companies have assessed limitations of oral psilocybin In a first-ever milestone, Cybin (NEO: CYBN) (NYSE American: CYBN) received approval from the U.S. Food and Drug Administration (“FDA”) (https://ibn.fm/QfXhX) to proceed with its planned phase 1/2a first in-human clinical trial and has started enrollment (https://ibn.fm/HxkKp). The study is designed to evaluate Cybin’s proprietary deuterated…

ThursdayJul 28, 2022 9:00 am

Pro Athletes Provide Specialized Advocacy for Odyssey Health, Inc.’s (ODYY) Solution for Concussion-related Brain Injuries

CDC estimates put the incidence of athlete concussion incidents at 5 to 10 percent of players Currently, there is no FDA-approved medicinal treatment for helping people with concussion injuries Odyssey Health Inc. is a company developing a drug-device combination to treat concussion patients in the first minutes after injury Retired pro soccer and football athletes Abby Wambach, Kurt Warner, and Brett Favre, have formed a Sports Advisory Board for Odyssey Health to help guide and promote public information regarding Odyssey’s treatment developments Wambach recently appeared on the Stock2Me podcast to discuss her interest in concussion research and her role on…

TuesdayJul 26, 2022 9:00 am

Odyssey Health, Inc. (ODYY), Determined to Introduce the Market’s First FDA Approved Concussion Treatment Drug

PBS News Hour estimates that, for college students, concussions cost between $446 million and $1.5 billion annually, while for high school students the cost ranges from $5.4 billion to $19.2 billion Odyssey, through its flagship product, PRV-002, hopes to offer the first FDA-approved drug treatment for concussions Once approved, Odyssey is confident that PRV-w002 will bring relief to thousands of victims, reduce the cost of concussion treatment and allow victims to lead normal, healthy, and productive lives The company is currently scheduling a meeting with the FDA to present findings from the phase I trial, as it identifies phase II…

MondayJul 25, 2022 11:15 am

Silo Pharma Inc. (SILO) Produced Initial Liposome Batch for Rheumatoid Arthritis Study

Silo Pharma produced initial batch of SPU-21 liposomes for rheumatoid arthritis study conducted by CRO Frontage Laboratories Recent company research revealed SPU-21 liposomes can target inflamed epithelium, suggesting use for targeted drug delivery SPU-21 can be used for development of fusion imaging molecules and/or nanoparticles to study arthritic pathogenesis Company recently announced positive results in subcutaneous delivery of novel liposomes vs. intravenous injection Silo Pharma (OTCQB: SILO), a developmental stage biopharmaceutical company that focuses on fusing traditional therapeutics with psychedelic research, recently announced it had produced an initial batch of SPU-21 liposomes for a rheumatoid arthritis study conducted by Frontage…

MondayJul 25, 2022 9:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Completes Acquisition of Largest-Ever DMT Study

Data from newly acquired study could accelerate clinical development of CYBN’s CYB004 by nine months The pivotal study was designed with four primary objectives Cybin’s proprietary substance has potential to effectively treat anxiety disorders, including GAD and SAD Cybin (NEO: CYBN) (NYSE American: CYBN) has completed the acquisition of the largest dimethyltryptamine (“DMT”) study to date, a Phase 1 N,N-DMT study that provides key data relating to the company’s proprietary CYB004 substance (https://ibn.fm/2Ab0T). Information from the study is expected to help the company accelerate by up to nine months its clinical development pathway of CYB004. “With the closing of this transaction…

FridayJul 22, 2022 9:00 am

Successful Early Testing of Concussion Therapy Drives Optimism for Odyssey Health, Inc. (ODYY) as Next-stage Trials are Readied

Medical technology innovator Odyssey Health Inc. is using clinical tests to establish the safety of a therapy designed to treat concussion injuries in its earliest moments The company is enthused by results from the early-stage testing and is preparing to design a Phase II/III trial that will target efficacy results in volunteer subjects, focusing particularly on members of the military Odyssey’s technology combines a synthetic medication with a specially designed application device that helps the medication cross the blood-brain barrier for immediate responsiveness following a mild traumatic brain injury (“mTBI”) Medication for concussion treatment remains an unmet need and Odyssey…

WednesdayJul 20, 2022 9:00 am

Odyssey Health, Inc. (ODYY) Responds to Growing Concerns About Concussion Head Injuries with Drug Device in Clinical Trial

As awareness of the long-term hazards of concussive head injuries for young athletes has increased during the past decade, advocates and business enterprises have stepped up to improve coach responsiveness to players’ condition While efforts primarily focus on assessing injury, Odyssey Health Inc. is developing a product it hopes to become the first drug device with FDA approval for treating a concussed patient after injury Odyssey is enrolling patients in a Phase 1 human clinical trial after completing pre-clinical studies in laboratory animals The medical research company’s assets include treatments for patients who may have undiagnosed heart disease, patients choking…

TuesdayJul 19, 2022 9:45 am

QSAM Biosciences Inc. (QSAM) Marks Milestone with Dosing of First Patient in CycloSam Clinical Trial

Treating patients with primary or secondary bone cancer remains goal, says company CEO Radiopharmaceuticals is a new class of drugs that delivers radiation therapy directly to cancer cells QSAM is working to develop CycloSam(R) as a breakthrough therapeutic for adult and pediatric bone cancer patients QSAM Biosciences (OTCQB: QSAM), a company developing a new class of drugs called radiopharmaceuticals, is leading the charge to evaluate a new treatment for bone cancer and other related, underserved diseases. The company’s pioneering efforts are evident as the first patient has completed treatment in the company’s clinical trial designed to study the effect of its…

WednesdayJul 13, 2022 9:00 am

Homing Peptides: Silo Pharma Inc. (SILO) Targets ADRs

Silo’s partnership with UMB could yield therapeutics that limit side effects through precisely targeted delivery On February 3, 2022, Silo Pharma (OTCQB: SILO) extended its research partnership with the University of Maryland, Baltimore (“UMB”) to explore potentially lifesaving joint-homing peptides that target inflamed endothelium (a thin membrane that lines the inside of the heart and blood vessels). The ability to target inflamed tissue (while bypassing healthy organs) suggests joint-homing peptides could deliver therapeutics or fusion imaging nanoparticles to specific diseased tissues. Better imaging, lower radiation and precision, targeted dosing could enhance the therapeutic effect of current and future therapeutics and…

MondayJul 11, 2022 12:00 pm

Odyssey Health, Inc.’s (ODYY) Sports Advisory Board Enhancing Public Awareness and Understanding of Traumatic Brain Injuries

Odyssey’s Sports Advisory Board (“SAB”) was formed in 2021 to enhance public awareness of traumatic brain injuries and concussion The board’s members – Abby Wambach, Kurt Warner, and Brett Favre – have had storied careers in their respective sports and have expressed hope that scientists will examine their brains after their death to advance their understanding of head trauma Abby Wambach has committed her brain to research, hoping her efforts will bridge the gender gap in understanding sports concussions in women Sports concussions are worse for women, with female athletes being more likely to develop a sports-related concussion than their…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Category: Uncategorized

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Cleared for Historic Study, Begins Enrolling Participants

Pro Athletes Provide Specialized Advocacy for Odyssey Health, Inc.’s (ODYY) Solution for Concussion-related Brain Injuries

Odyssey Health, Inc. (ODYY), Determined to Introduce the Market’s First FDA Approved Concussion Treatment Drug

Silo Pharma Inc. (SILO) Produced Initial Liposome Batch for Rheumatoid Arthritis Study

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Completes Acquisition of Largest-Ever DMT Study

Successful Early Testing of Concussion Therapy Drives Optimism for Odyssey Health, Inc. (ODYY) as Next-stage Trials are Readied

Odyssey Health, Inc. (ODYY) Responds to Growing Concerns About Concussion Head Injuries with Drug Device in Clinical Trial

QSAM Biosciences Inc. (QSAM) Marks Milestone with Dosing of First Patient in CycloSam Clinical Trial

Homing Peptides: Silo Pharma Inc. (SILO) Targets ADRs

Odyssey Health, Inc.’s (ODYY) Sports Advisory Board Enhancing Public Awareness and Understanding of Traumatic Brain Injuries

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search